51 Results for "

MPTP

" in MedChemExpress (MCE) Product Catalog:
Products (51)

51 Results for "MPTP" in MCE Product Catalog:

814
Erastin
Erastin
0 Images
814 Publications Verification
Cat. No.: HY-15763
CAS No.: 571203-78-6
Purity:  99.62%
Target:  

VDAC Ferroptosis Disulfidptosis

Research Areas:  

Cancer

Erastin is a ferroptosis inducer. Erastin exhibits the mechanism of ferroptosis induction related to ROS and iron-dependent signaling. Erastin inhibits voltage-dependent anion channels (VDAC2/VDAC3) and accelerates oxidation, leading to the accumulation of endogenous reactive oxygen species. Erastin also disrupts mitochondrial permeability transition pore (mPTP) with anti-tumor activity. Furthermore, Erastin can block the uptake of cystine mediated by SLC7A11 and also spares UMRC6-EV and -C91A cells from disulfidptosis under glucose starvation .
87
MPTP hydrochloride
MPTP hydrochloride
0 Images
87 Cited Publications
Cat. No.: HY-15608
CAS No.: 23007-85-4
Purity:  99.52%
Target:  

Dopamine Receptor Apoptosis

Research Areas:  

Neurological Disease Inflammation/Immunology

MPTP hydrochloride is a brain penetrant dopaminergic neurotoxin. MPTP hydrochloride can be used to induce Parkinson’s Disease model. MPTP hydrochloride, a precusor of MPP +, induces apoptosis . MPTP hydrochloride has been verified by MCE with professional biological experiments.
87
MPTP
MPTP
0 Images
87 Cited Publications
Cat. No.: HY-W114750
CAS No.: 28289-54-5
Target:  

Dopamine Receptor Apoptosis

Research Areas:  

Neurological Disease Inflammation/Immunology

MPTP (1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine) is a brain penetrant dopamine neurotoxin. MPTP can be used to induce Parkinson’s Disease model. MPTP, a precusor of MPP +, induces apoptosis .
34
MPP+ iodide
MPP+ iodide
0 Images
34 Cited Publications
Cat. No.: HY-W008719
CAS No.: 36913-39-0
Target:  

Mitochondrial Metabolism

Research Areas:  

Neurological Disease

MPP+ iodide, a toxic metabolite of the neurotoxin MPTP, causes symptom of Parkinson's disease in animal models by selectively destroying dopaminergic neurons in substantia nigra. MPP+ iodide is taken up by the dopamine transporter into dopaminergic neurons where it exerts its neurotoxic action on mitochondria by affecting complex I of the respiratory chain. MPP+ iodide is also a high affinity substrate for the serotonin transporter (SERT) .
7
ER-000444793
ER-000444793
0 Images
7 Cited Publications
Cat. No.: HY-100852
CAS No.: 792957-74-5
Purity:  ≥98.0%
Target:  

Mitochondrial Metabolism

Research Areas:  

Cancer

ER-000444793 is a potent inhibitor of mitochondrial permeability transition pore (mPTP) opening. ER-000444793 inhibits mPTP with an IC50 of 2.8 μM.
3
Atractyloside A
Atractyloside A
0 Images
3 Cited Publications
Cat. No.: HY-N0237
CAS No.: 126054-77-1
Category:  

Terpenoids Sesquiterpenes Other Diseases Plants Compositae Disease Research Fields Erythrina sigmoidea Hua

Target:  

Toll-like Receptor (TLR) MyD88 NF-κB Mitochondrial Metabolism Interleukin Related Aquaporin

Atractyloside A is an orally active inhibitor of the TLR4/MyD88/NF-κB signaling pathway and also an opener of the mitochondrial permeability transition pore (MPTP). Atractyloside A interferes with the activation of the TLR4/MyD88/NF-κB pathway, thereby inhibiting intestinal inflammatory responses. Atractyloside A reverses mucin synthesis impairment, improves intestinal barrier integrity, and restores homeostasis by altering the composition of the gut microbiota. Atractyloside A can be used in studies related to spleen deficiency diarrhea and myocardial injury .
[D-Ala2]-GIP (human)
[D-Ala2]-GIP (human)
0 Images
Cat. No.: HY-P3247
CAS No.: 444073-04-5
Target:  

Insulin Receptor

Research Areas:  

Neurological Disease Metabolic Disease

[D-Ala2]-GIP (human) is a GIP receptor agonist (EC50 = 630 pM). [D-Ala2]-GIP (human) improves glucose tolerance. [D-Ala2]-GIP (human) shows neuroprotective activity in MPTP (HY-W114750)-induced Parkinson's disease model. [D-Ala2]-GIP (human) also improves cognitive function and hippocampal synaptic plasticity in obese diabetic rats. [D-Ala2]-GIP (human) can be used for research of type 2 diabetes, Parkinson's disease, etc
NRG1271
NRG1271
0 Images
Cat. No.: HY-175715
CAS No.: 3077720-24-9
Target:  

Mitochondrial Metabolism

Research Areas:  

Neurological Disease

NRG1271 is an orally active mitochondrial permeability transition pore (mPTP) inhibitor with blood-brain barrier penetration. NRG1271 can be used for the study of Neurological Disease .
Talatisamine
Talatisamine
0 Images
Cat. No.: HY-N0663
CAS No.: 20501-56-8
Category:  

Alkaloids Pyrrole Alkaloids Ranunculaceae  Aconitum carmichaeli Debx. Plants

Target:  

Mitochondrial Metabolism Cyclophilin Potassium Channel

Talatisamine is an orally active cyclophilin D activator isolated from the roots of Aconitum carmichaeli Debx. Talatisamine exerts biological functions by activating cyclophilin D, inhibiting Ca 2+-dependent opening of the mitochondrial permeability transition pore (mPTP) (IC50=78 μM), and blocking delayed rectifier K + channels (IC50=146 μM). Talatisamine possesses both antioxidant and membrane-stabilizing properties, effectively inhibits lipid peroxidation and protects mitochondrial membrane function. Talatisamine exhibits multiple activities including antiarrhythmic, hypotensive, anti-inflammatory, anticancer and neuroprotective effects. Talatisamine finds applications in the research of ischemic diseases, rheumatoid arthritis, inflammation-related diseases and Alzheimer's disease .
Docosahexaenoic acid (Standard)
Docosahexaenoic acid (Standard)
0 Images
Cat. No.: HY-B2167R
CAS No.: 6217-54-5
Synonyms: DHA (Standard); Cervonic acid (Standard)
Category:  

Human Gut Microbiota Metabolites Microorganisms Ketones, Aldehydes, Acids Disease markers Endogenous metabolite Cardiovascular System Disorder

Target:  

Reference Standards Endogenous Metabolite

Docosahexaenoic acid (Standard) is the analytical standard of Docosahexaenoic acid. This product is intended for research and analytical applications. Docosahexaenoic Acid (DHA) is an omega-3 fatty acid abundantly present brain and retina. It can be obtained directly from fish oil and maternal milk. In Vitro: Docosahexaenoic acid (DHA) is essential for the growth and functional development of the brain in infants. DHA is also required for maintenance of normal brain function in adults. The inclusion of plentiful DHA in the diet improves learning ability and memory . DHA is an essential requirement in every step of brain development like neural cell proliferation, migration, differentiation, synaptogenesis. The multiple double bonds and unique structure allow DHA to impart special membrane characteristics for effective cell signaling. Many development disorders like dyslexia, autism spectrum disorder, attention deficit hyperactivity disorder, schizophrenia etc. are causally related to decreased level of DHA . DHA is a potent RXR ligand inducing robust RXR activation already at low micro molar concentrations. The EC50 for RXRα activation by DHA is about 5-10 μM fatty acid . In Vivo: Docosahexaenoic acid administration over 10 weeks significantly reduces the number of reference memory errors, without affecting the number of working memory errors, and significantly increases the docosahexaenoic acid content and the docosahexaenoic acid/arachidonic acid ratio in both the hippocampus and the cerebral cortex . DHA treatment exerts neuroprotective actions on an experimental mouse model of PD. There is a decrease tendency in brain lipid oxidation of MPTP mice but it does not significantly .
Tetradecanoylcarnitine
Tetradecanoylcarnitine
0 Images
Cat. No.: HY-113201
CAS No.: 25597-07-3
Purity:  ≥98.0%
Category:  

Ketones, Aldehydes, Acids Disease markers Metabolic Disease Endocrine diseases Endogenous metabolite Disease Research Fields

Target:  

Endogenous Metabolite

Tetradecanoylcarnitine is an acylcarnitine involved in mitochondrial β-oxidation of long-chain saturated fatty acids and fatty acid metabolism. Tetradecanoylcarnitine serves as a biomarker for very long-chain acyl-CoA dehydrogenase deficiency and MPTP (HY-15608)-induced Parkinson's disease. Tetradecanoylcarnitine exhibits a characteristic significant elevation in plasma levels in patients with sarcopenia, including those complicated with hypertension, and this elevation is closely associated with an increased risk of death. Tetradecanoylcarnitine is widely used in research on the pathological mechanisms of diseases such as Parkinson's disease and sarcopenia .
Drp1 peptide inhibitor P110 TFA
Drp1 peptide inhibitor P110 TFA
0 Images
Cat. No.: HY-P6437A
Target:  

Dynamin

Research Areas:  

Cardiovascular Disease Neurological Disease

Drp1 peptide inhibitor P110 (Compound P110) TFA is a selective Drp1 peptide inhibitor with neuroprotective properties. Drp1 peptide inhibitor P110 TFA can inhibit the activation of Drp1, prevent MPTP (HY-15608)-induced Drp1 mitochondrial translocation, and alleviate MPTP-induced dopaminergic neuron loss, dopaminergic nerve terminal damage, and behavioral deficits, and can be used in the study of Alzheimer's disease. Additionally, Drp1 peptide inhibitor P110 TFA can reduce mitochondrial damage and organ injury in animal models of Huntington's disease, cerebral ischemic injury, and myocardial infarction .
C105SR
C105SR
0 Images
Cat. No.: HY-157088
Purity:  99.49%
Target:  

Caspase Apoptosis Cyclophilin

Research Areas:  

Others

C105SR is a cyclophilin D (CypD) inhibitor targeting to peptidyl-prolylcis-trans isomerase (PPIase). C105SR inhibits mitochondrial permeability transition opening (mPTP) with an IC 50 of 5 nM. C105SR inhibits hypoxia and reoxygenation inudced hepatocyte apoptosis and increases the level of calcium retention capacity (CRC). C105SR exhibits hepaprotective effect in ischaemia-reperfusion injury (IRI) mouse model .
GNX-865
GNX-865
0 Images
Cat. No.: HY-119909
CAS No.: 1223568-82-8
Purity:  98.09%
Target:  

Mitochondrial Metabolism

Research Areas:  

Cardiovascular Disease

GNX-865 is a mitochondrial permeability transition pore (mPTP) inhibitor that protects against ischemia-reperfusion injury in vivo .
Drp1 peptide inhibitor P110
Drp1 peptide inhibitor P110
0 Images
Cat. No.: HY-P6437
CAS No.: 2770267-63-3
Target:  

Dynamin

Research Areas:  

Cardiovascular Disease Neurological Disease

Drp1 peptide inhibitor P110 (Compound P110) is a selective Drp1 peptide inhibitor with neuroprotective properties. Drp1 peptide inhibitor P110 can inhibit the activation of Drp1, prevent MPTP-induced Drp1 mitochondrial translocation, and alleviate MPTP-induced dopaminergic neuron loss, dopaminergic nerve terminal damage, and behavioral deficits, and can be used in the study of Alzheimer's disease. Additionally, Drp1 peptide inhibitor P110 can reduce mitochondrial damage and organ injury in animal models of Huntington's disease, cerebral ischemic injury, and myocardial infarction .
MAO-IN-M30 dihydrochloride
MAO-IN-M30 dihydrochloride
0 Images
Cat. No.: HY-131036
CAS No.: 64821-19-8
Purity:  99.25%
Target:  

Monoamine Oxidase

Research Areas:  

Neurological Disease

MAO-IN-M30 dihydrochloride is an orally active, brain-permeable, and brain selective irreversible MAO-A (IC50=37 nM) and MAO-B (IC50=57 nM) inhibitor. MAO-IN-M30 dihydrochloride is a potent iron chelator and radical scavenger. MAO-IN-M30 dihydrochloride has a neuroprotective effect against Dexamethasone-induced brain cell apoptosis. MAO-IN-M30 dihydrochloride also exhibits neurorestorative activity in post MPTP and lactacystin models of Parkinson's disease . MAO-IN-M30 (dihydrochloride) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
Adrogolide hydrochloride
Adrogolide hydrochloride
0 Images
Cat. No.: HY-118956
CAS No.: 166591-11-3
Purity:  98.01%
Synonyms: ABT-431 hydrochloride; DAS-431 hydrochloride
Target:  

Dopamine Receptor

Research Areas:  

Neurological Disease

Adrogolide hydrochloride (ABT-431 hydrochloride) is a chemically stable prodrug that can convert to the dopamine D1 receptor agonist A-86929. Adrogolide hydrochloride ameliorates the MPTP (HY-15608)-induced Parkinson's Disease in marmoset model, reduces the dyskinesias tendency. Adrogolide hydrochloride reverses Risperidone (HY-11018)-induced cognitive deficits in monkey .
ATP synthase inhibitor 1
ATP synthase inhibitor 1
0 Images
Cat. No.: HY-112715
CAS No.: 1023043-30-2
Purity:  99.56%
Target:  

ATP Synthase

Research Areas:  

Cardiovascular Disease

ATP synthase inhibitor 1 is a potent inhibitor of c subunit of the F1/FO-ATP synthase complex, inhibits mitochondrial permeability transition pore (mPTP) opening, does not affect ATP levels .
MPP+-d3iodide
MPP+-d3iodide
0 Images
Cat. No.: HY-W008719S
CAS No.: 207556-07-8
MPP+-d3 (iodide) is deuterium labeled MPP+ (iodide). MPP+ iodide, a toxic metabolite of the neurotoxin MPTP, causes symptom of Parkinson's disease in animal models by selectively destroying dopaminergic neurons in substantia nigra. MPP+ iodide is taken up by the dopamine transporter into dopaminergic neurons where it exerts its neurotoxic action on mitochondria by affecting complex I of the respiratory chain. MPP+ iodide is also a high affinity substrate for the serotonin transporter (SERT) .
mPTP-IN-1
mPTP-IN-1
0 Images
Cat. No.: HY-172959
CAS No.: 554414-59-4
Target:  

Mitochondrial Metabolism

Research Areas:  

Cardiovascular Disease

mPTP-IN-1 (Compound 14e) is a mitochondrial permeability transition pore (mPTP) inhibitor. mPTP-IN-1 blocks calcium-induced mPTP opening by targeting the C subunit of ATP synthase. mPTP-IN-1 can be used to study myocardial ischemia/reperfusion injury (IRI) .
Assay Types